Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INXN-3001
- Development stage
- Phase 1
- Lead developer
- Precigen
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intratumoral
01
Overview
INXN-3001 is a gene and cell therapy product that utilizes autologous dendritic cells transduced with an adenoviral vector encoding the interleukin 12 (IL‑12) gene under the control of the RheoSwitch Therapeutic System (RTS). This system allows for regulated, ligand-dependent expression of IL‑12 in vivo. The therapy is designed to stimulate anti-tumor immune responses by activating the interleukin‑12 receptor (IL‑12R) pathway. INXN‑3001 has been investigated primarily for cancer indications, including melanoma and glioblastoma, via intratumoral injection. The product was initially developed by Precigen and has also involved Alaunos Therapeutics (formerly Ziopharm Oncology), with Intrexon Corporation providing key technology[1][2][6][8].
- Other names
- Dendritic Cell-RheoSwitch Therapeutic System-Interleukin-12
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on INXN-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INXN-3001.